Avenanthramides in Obesity-Related Metabolic Dysfunction: Mechanisms, Evidence Attribution, and Translational Priorities
Nutrients · 2026
DOI: 10.3390/nu18183066 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrients, 2026. Verfasst von Xiaoyu Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Sports Training, Wuhan Sports University, Wuhan 430079, China. Hauptthemen laut MEDLINE: Obesity, ortho-Aminobenzoates, Avena, Metabolic Diseases. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Peking University Health Science Center, Fundamental Research Funds, Peking University Medical–Qingyan Boshi Joint Laboratory for Skin Nutrition and Anti-Aging.
Abstract (Originalsprache)
Background
Obesity-related metabolic dysfunction includes adipose inflammation, hepatic steatosis, insulin resistance, dyslipidemia, and intestinal disturbances. Avenanthramides are oat-specific phenolic amides, and their contribution to metabolic responses to oat foods is difficult to attribute because beta-glucan and the wider oat matrix can affect the same endpoints. This narrative review examines their mechanisms, exposure biology, evidence attribution, and translational readiness.
Methods
Cell, animal, pharmacokinetic, and human studies were organized by chemical definition and intervention format, including purified congeners, characterized foods, enriched matrices, and whole-oat products. Parent compounds, circulating metabolites, target tissues, and clinical outcomes were interpreted separately.
Results
In cell and animal models, avenanthramides influence NF-κB-related inflammation, redox regulation, hepatic insulin signaling, glucose production, fatty-acid metabolism, and intestinal ecology. Human studies demonstrate dietary exposure to parent compounds and metabolites, while clinical evidence comes mainly from small enriched-food exercise studies. Among the studies identified and appraised in this narrative review, none established an avenanthramide-specific effect on adiposity, liver fat, insulin sensitivity, dyslipidemia, or other cardiometabolic outcomes.
Conclusions
The current literature supports measurable exposure and candidate mechanisms; a validated anti-obesity effect requires targeted clinical trials. Next studies need stable, analytically defined preparations, metabolite-informed dose selection, matched food controls, and trials that link measured exposure with prespecified clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Sports Training, Wuhan Sports University, Wuhan 430079, China.
- School of Sports Science, Beijing Sport University, Beijing 100084, China.
- Department of Sports Journalism and Management, Henan Sport University, Zhengzhou 450044, China.
ORCID-Profile: Ziyang Li, Shuning Liu, Chang Liu
Förderung
- the Peking University Health Science Center
- Fundamental Research Funds
- Peking University Medical–Qingyan Boshi Joint Laboratory for Skin Nutrition and Anti-Aging
- Peking University Health Science Center
- Youth Program of the Ministry of Education, Humanities, and Social Sciences Fund
- Beijing Higher Education Society’s Sub-Committee on University Student Employment and Entrepreneurship Research
- BSU Project
- National Natural Science Foundation of China
Zitieren
APA
Zhang, X., Sun, H., Tao, B., Li, Z., Liu, S., Zhang, H., Liu, C., & Wang, J. (2026). Avenanthramides in Obesity-Related Metabolic Dysfunction: Mechanisms, Evidence Attribution, and Translational Priorities. Nutrients. https://doi.org/10.3390/nu18183066
Vancouver
Zhang X, Sun H, Tao B, Li Z, Liu S, Zhang H, et al. Avenanthramides in Obesity-Related Metabolic Dysfunction: Mechanisms, Evidence Attribution, and Translational Priorities. Nutrients. 2026. doi:10.3390/nu18183066
BibTeX
@article{Zhang2026,
author = {Zhang, Xiaoyu and Sun, Hao and Tao, Biaoxu and Li, Ziyang and Liu, Shuning and Zhang, Haojie and Liu, Chang and Wang, Jiatong},
title = {Avenanthramides in Obesity-Related Metabolic Dysfunction: Mechanisms, Evidence Attribution, and Translational Priorities},
journal = {Nutrients},
year = {2026},
doi = {10.3390/nu18183066}
}
EUVIMED